Zelluna Immunotherapy appoints Miguel Forte as Chief Executive Officer

Appointment to drive Zelluna through next stage of international clinical-phase development

Oslo, Norway, November 2, 2017 - Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, today announces the appointment of Miguel Forte as chief executive officer (CEO).


Zelluna Immunotherapy awarded NOK 14 million (USD 1.7 million) from the NRC

The Norwegian Research Council (NRC) has awarded Zelluna Immunotherapy NOK 14 million over a period of 3.5 years through the BIA program for the development of T cell based cancer therapy.

This project supports the overall strategy of the company in bringing new and innovative treatment options for cancer patients.